Puma Biotechnology (PBYI) EBT (2010 - 2026)

Puma Biotechnology (PBYI) has 17 years of EBT data on file, last reported at -$3.4 million in Q1 2026.

• Quarterly EBT fell 204.9% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.1 million (up 269.98% YoY) and the FY2025 annual result came in at $35.8 million, changed N/A from the prior year.
• EBT fell to -$3.4 million in Q1 2026, from $17.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $20.6 million in Q3 2024 to a low of -$11.9 million in Q4 2024.
• A 5-year average of $3.3 million and a median of $2.3 million in 2023 frame the typical range for EBT.
• Annual changes were most pronounced in 2023 — EBT surged 2150.85% — and 2024, when it slumped 396.83%.
• Tracing PBYI's EBT over 5 years: stood at -$5.3 million in 2022, then jumped by 341.04% to $12.8 million in 2023, then slumped by 192.64% to -$11.9 million in 2024, then jumped by 244.22% to $17.1 million in 2025, then tumbled by 120.03% to -$3.4 million in 2026.
• The last three EBT figures came in at -$3.4 million (Q1 2026), $17.1 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.